Last reviewed · How we verify
Carvedilol 25mg
At a glance
| Generic name | Carvedilol 25mg |
|---|---|
| Also known as | Coreg |
| Sponsor | Ahn-Gook Pharmaceuticals Co.,Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cardiac Changes in Early Parkinson's Disease: A Follow up Study (PHASE2)
- Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136) (PHASE2)
- Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab (PHASE1)
- Effects of Sleep Deprivation and Adrenergic Inhibition on Glymphatic Flow in Humans (EARLY_PHASE1)
- Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification (PHASE2)
- Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol (PHASE4)
- Effect of Carvedilol Rapid Up-Titration in Patients With Heart Failure With Reduced Ejection Fraction (PHASE4)
- Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol 25mg CI brief — competitive landscape report
- Carvedilol 25mg updates RSS · CI watch RSS
- Ahn-Gook Pharmaceuticals Co.,Ltd portfolio CI